The renin–angiotensin system (RAS) and obesity have been implicated in vascular outward remodeling, including aneurysms, but the precise mechanisms are not yet understood. We investigated the effect of the angiotensin receptor type 1 (AT1-receptor) antagonist telmisartan on aortic outward remodeling in a diet-induced obesity model in mice. C57/Black6J mice were fed either a low-fat diet (LFD) or a high-fat diet (HFD) for 14 weeks. One group of HFD mice was additionally exposed to telmisartan (3 mg/kg per day) for the last 4 weeks. HFD led to aortic outward remodeling, characterized by increased proteolysis, along with structural changes, such as fragmentation of elastic fibers and decreased elastin content. Vascular damage was associated with up-regulation of matrix metalloproteinase (MMP)-2 (MMP-2), MMP-3, MMP-12, cathepsin D, and cathepsin B. HFD aortae exhibited an enhanced inflammatory status, characterized by tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) colocalized with adipocytes in the adventitia. HFD resulted in a significant increase in aortic dimensions, evident by ultrasound measurements. Telmisartan abolished aortic dilatation and preserved elastin content. HFD induced enhanced expression of aortic MMP-2, MMP-9, and TNF-α was abrogated by telmisartan. Adventitial proteolytic and inflammatory factors were also examined in samples from human abdominal aneurysms. The expression of TNF-α, IL-1β, and MMP-9 was higher in the adventitial fat of diseased vessels compared with healthy tissues. Finally, adipocytes treated with TNF-α showed enhanced MMP-2, MMP-3, and cathepsin D, which was prevented by telmisartan. Taken together, HFD in mice induced aortic dilatation with up-regulation of matrix degrading and inflammatory pathways similar to those seen in human aortic aneurysmatic tissue. The HFD-induced vascular pathology was reduced by AT1-receptor antagonist telmisartan.
Skip Nav Destination
Article navigation
August 2017
-
Cover Image
Cover Image
Human vascular smooth muscle cell derived from a skin precursor. Subjects with type-2 diabetes have fewer skin-derived precursors in their skin. Vascular smooth muscle cells derived from skin-derived precursors from subjects with type-2 diabetes carry persistent signatures of disease even weeks after being removed from the patient. Thus, skin-derived precursors may be a promising platform to study type-2 diabetes associated vascular disease in a dish. In Clinical Science volume 131, issue 15, Steinbach et al. describe new approach to studying human vascular smooth muscle cell (VSMC) pathophysiology by examining VSMCs differentiated from progenitors found in skin (see pages 1801-1814).
Research Article|
July 13 2017
AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice
Friedrich Krueger;
Friedrich Krueger
*
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
Search for other works by this author on:
Kai Kappert;
Kai Kappert
*
2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Center for Cardiovascular Research (CCR), Germany
3DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany
Search for other works by this author on:
Anna Foryst-Ludwig;
Anna Foryst-Ludwig
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
3DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany
Search for other works by this author on:
Frederike Kramer;
Frederike Kramer
2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Center for Cardiovascular Research (CCR), Germany
Search for other works by this author on:
Markus Clemenz;
Markus Clemenz
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
Search for other works by this author on:
Aleksandra Grzesiak;
Aleksandra Grzesiak
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
Search for other works by this author on:
Manuela Sommerfeld;
Manuela Sommerfeld
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
Search for other works by this author on:
Jan Paul Frese;
Jan Paul Frese
4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Department of Vascular Surgery, Germany
Search for other works by this author on:
Andreas Greiner;
Andreas Greiner
4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Department of Vascular Surgery, Germany
Search for other works by this author on:
Ulrich Kintscher;
Ulrich Kintscher
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
3DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany
Search for other works by this author on:
Thomas Unger;
Thomas Unger
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
5CARIM - School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands
Search for other works by this author on:
Elena Kaschina
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; and Berlin Institute of Health, Institute of Pharmacology, Center for Cardiovascular Research (CCR), Germany
Correspondence: Elena Kaschina ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 10 2017
Revision Received:
June 21 2017
Accepted:
June 23 2017
Accepted Manuscript online:
June 23 2017
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2017
Clin Sci (Lond) (2017) 131 (15): 1989–2005.
Article history
Received:
February 10 2017
Revision Received:
June 21 2017
Accepted:
June 23 2017
Accepted Manuscript online:
June 23 2017
Citation
Friedrich Krueger, Kai Kappert, Anna Foryst-Ludwig, Frederike Kramer, Markus Clemenz, Aleksandra Grzesiak, Manuela Sommerfeld, Jan Paul Frese, Andreas Greiner, Ulrich Kintscher, Thomas Unger, Elena Kaschina; AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice. Clin Sci (Lond) 1 August 2017; 131 (15): 1989–2005. doi: https://doi.org/10.1042/CS20170131
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.